Article: Schering-Plough Announces European Union's CPMP Recommends Approval of Desloratadine for Seasonal Allergies.

KENILWORTH, N.J., Oct. 10 /PRNewswire/ --

Schering-Plough Corporation (NYSE: SGP) today announced that the Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medicinal Products (EMEA) has issued a positive opinion recommending approval of the nonsedating antihistamine desloratadine 5 mg as a once-daily treatment for seasonal allergic rhinitis (SAR). Upon final approval, desloratadine will be marketed within the European community primarily under the brand name AERIUST(TM).

A new chemical entity, desloratadine is a long-acting, H1 receptor antagonist, blocking the effects of histamine release in the body. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!